SANARA MEDTECH INC (SMTI)
Health Care · surgical devices and biomaterials · NASDAQ
Sanara MedTech is a surgical products company focused on soft tissue repair and bone fusion technologies, currently pending acquisition by MiMedx Group.
What SANARA MEDTECH INC does
Sanara MedTech is a medical technology company that develops and commercializes surgical products for soft tissue repair and bone fusion. Its portfolio includes collagen-based wound management products, advanced surgical irrigation solutions, and various bone matrix implants used in operating rooms and sterile environments. The company focuses on enhancing clinical outcomes and reducing total healthcare costs by providing innovative surgical solutions.
Recent developments
Sanara MedTech announced a definitive merger agreement to be acquired by MiMedx Group, with completion pending customary closing conditions. The company is also preparing for the first quarter 2027 launch of OsStic, a synthetic injectable structural bio-adhesive bone void filler.
From SANARA MEDTECH INC's filing of 2026-08-11.
Themes: surgical innovation, regenerative medicine, wound care, orthopedic surgery, bone grafting
Fundamentals
- Price$35.05 as of 2026-10-08 close
- Market cap$322M as of 2026-08-07 (share count; price 2026-10-08)
- 1-year return+8.4% 2025-10-08 close $32.33 → 2026-10-08 close $35.05
- P/En/a negative earnings
- Net margin-36.4% FY2025, SEC XBRL
- Gross margin+92.7% FY2025, SEC XBRL
- ROE-632.5% FY2025, SEC XBRL
- Debt / equity6.58 as of 2026-09-02
- Revenue growth (YoY)-10.8% as of 2026-09-02
- Revenue CAGR (3y)+31.0% SEC XBRL
- Beta1.09 as of 2026-09-02
- Last reported earnings2026-08-11 SEC EDGAR Form 8-K (Item 2.02)
How SMTI compares in its sector
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-02
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-02
- gross margintop 10% 189 covered Health Care peers, as of 2026-09-02
- return on equitybottom 10% 510 covered Health Care peers, as of 2026-09-02
- 3-year revenue CAGRtop 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How SANARA MEDTECH INC looks technically
SANARA MEDTECH INC (SMTI) is trading 41.8% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 57 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 35, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 63, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 13 trading days ago. It is 0.8% below its 52-week high (its highest price of the past year). Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 1% of the past ~6 months), which often precedes a bigger move.
Trend
8
| Distance from the 200-day | it is trading 41.8% above its 200-day average, the long-term trend line — a longer-term uptrend | +41.8% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $34.67 | $34.67 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $24.72 | $24.72 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 16 calendar days ago — the swings before that are what the structure reading is measured on | 16 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that upward direction; the labelling fails if price closes below 26. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a completed three-part correction. | possible upward five-wave sequence, in wave 4 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 57 trading days ago — a "golden cross", a bullish long-term signal | 57 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 35, with buyers in control | 34.7 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 63, neither overbought (above 70) nor oversold (below 30) | 63.2 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($34.63 to $35.34) — its "stochastic" reading is 60 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 59.6 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 38 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $35.34 | $35.34 |
|---|---|---|
| From the 52-week high | it is 0.8% below its 52-week high (its highest price of the past year) | -0.8% |
| Above the 52-week low | it is 118.4% above its 52-week low (its lowest price of the past year) | +118.4% |
| Below the 52-week high | it is at or near its highest point of the past year | 0.8% |
| Since a 20-day breakout | it made a new 20-day high about 13 trading days ago | 13 sessions |
| Since a 55-day breakout | it made a new 55-day high about 13 trading days ago | 13 sessions |
| All-time high | its highest closing price on record is $7800.00 (set on 1997-08-19) | $7800.00 |
| Given back of the 52-week move | over the past year its closes ranged ($16.34 to $35.28), and it has given back essentially none of its rise from last year’s low — 1% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $22.97 to $23.58. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 1.2% |
| From the all-time high | it is 99.6% below its all-time high | -99.5% |
| Nearest price level | it is trading 0.6% below a resistance level at $35.24 — a price it turned at 7 times since 2024-10-22, most recently on 2026-09-22. Since 2024-10-08 it has 15 such levels below the current price and 3 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +0.6% |
| All-time low | its lowest closing price on record is $2.00 (set on 2015-09-15) | $2.00 |
| Above the all-time low | it is 1652.5% above its all-time low | +1,653% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 1% of the past ~6 months), which often precedes a bigger move | 1st percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.2523 between its high and its low — about 0.7% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.2523 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $34.85 and $35.25 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $34.85 – $35.05 – $35.25 |
| Typical daily range (% of price) | its price moves about 0.7% in a typical session — among the calmest in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 0.7% |
| Stretch from the 200-day average | it is trading 41.0 daily ranges above its 200-day average price (41.8% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale. Read that multiple with care: this company's daily range is unusually small (about 0.7% of its price), which is what makes the multiple large — a stock trading in a narrow band near a takeover price does this | 41.0 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.93× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
2
| Since a hammer | 4 sessions ago, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | 4 sessions ago |
|---|---|---|
| Since a bullish engulfing | 3 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 3 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-10-08 at essentially the same price it closed at the session before — no meaningful overnight gap | -0.1% |
|---|---|---|
| Open gap | it gapped 10.6% above the previous close 49 sessions ago and has not traded back through the level it left behind at 30.25 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +10.6% |
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 1.0 percentage points (the stock gained 0.0% while the market gained 1.0%) | -1.0% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 40.8 percentage points (the stock gained 44.7% while the market gained 3.8%) | +40.8% |
| vs market, 6 months | over the past 6 months this stock beat the market by 86.4 percentage points (the stock gained 103.9% while the market gained 17.5%) | +86.5% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 6.6 percentage points (the stock gained 8.4% while the market gained 15.0%) | -6.6% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a strong uptrend, with buyers in control, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: MACD momentum is negative — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 7.8% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thick, spanning 13.8% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | +7.8% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 17% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $29.97 — a volume-weighted average of daily closes over 192 sessions, not a true tick-by-tick VWAP. | +17.0% |
|---|---|---|
| Vs the average paid since it last reported | the price is 1% above the average price paid since it last reported on 2026-08-11 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $34.68 — a volume-weighted average of daily closes over 42 sessions, not a true tick-by-tick VWAP. | +1.1% |
Price levels it has turned at before
SMTI last closed at $35.05 on 2026-10-08. Since 2024-10-08 it has turned at 15 prices below its last close and 3 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $35.24 | Resistance | 0.6% above the last close | turned there 7 times · 2024-10-22 to 2026-09-22 |
| $34.34 | Support | 2.0% below the last close | turned there five times · 2024-12-05 to 2026-08-18 |
| $36.13 | Resistance | 3.1% above the last close | turned there twice · 2025-02-26 to 2025-09-08 |
| $33.44 | Support | 4.6% below the last close | turned there three times · 2025-02-13 to 2026-08-10 |
| $32.51 | Support | 7.3% below the last close | turned there twice · 2024-11-12 to 2025-09-03 |
| $38.84 | Resistance | 10.8% above the last close | turned there three times · 2024-11-13 to 2025-01-22 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes below $26.00.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $29.17 and $32.42 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a completed three-part correction, which fails on a close above $35.34.
This reading has stood for 8 trading days, since 2026-09-29.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Near the 52-week high · in a Bollinger Band volatility squeeze · in a strong, established uptrend (ADX) · beating the market · Least volatile (2% or less typical daily range) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low · bollinger bands
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$35.00 range $35.00 – $35.00
Analyst estimates, as of 2026-10-05. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for SMTI
- Consensus EPS estimate$0.02 next reporting period, as of 2026-10-05
- Estimate change, 30 days+$0.09 from -$0.07, on 2026-08-31, 35-day window
- Readings revised upward14% of 7 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Uncertainty regarding the consummation and integration of the pending merger with MiMedx Group.","Intense competition in the medical technology market and the potential for superior competing products.","Dependence on the commercial success of key products like CellerateRX Surgical and the ability to maintain distribution models."]
What changed in the latest 10-Q
AI-assisted comparison of SMTI's 10-Q filed 2026-05-12 against the prior one filed 2025-11-12.
Management's Discussion & Analysis (MD&A)
- Added:
- Reference to Form 10-K for year ended December 31, 2025 (newer filing, filed 2026-05-12)
- Addition of TEXAGEN Amniotic Membrane Allograft in soft tissue repair products description
- Addition of ACTIGEN Verified Inductive Bone Matrix in bone fusion products description
- Updated pipeline description: 'advancing a strong pipeline of next-generation products that supports and extends our surgical strategy of "Prepare, Promote and Protect."' (newer filing)
- Updated section header from 'Summary of Our Product, Service and Technology Offerings and Development Programs' to 'Summary of Our Key Products and Development Programs' (newer filing)
- Removed:
- Reference to Form 10-K for year ended December 31, 2024 (older filing, filed 2025-11-12)
- Reference to 'wound and skin services' in forward-looking statements topic examples
- Phrase 'services and technologies' in OVERVIEW - changed to focus on products only
- Phrase 'and patients' after 'treatments' in OVERVIEW goal statement
- Reference to 'physicians, clinics, and post-acute care settings' in customer description - newer version states 'surgeons at hospitals and surgical centers'
- Reference to 'advanced wound care markets' - newer version removes this market reference
- Phrase about 'constantly seeking long-term strategic partnerships with a focus on products that improve outcomes at a lower overall cost'
- Product name variation: 'CellerateRX Surgical Activated Collagen' changed to 'CellerateRX Surgical' (without 'Activated Collagen')
- Reference to 'CellerateRX Surgical powder' specification - newer version generalizes to 'CellerateRX Surgical'
- Extended product description phrase 'The majority of CellerateRX Surgical products are used for a variety of surgical wounds'
- Reference to 'Surgeons use CellerateRX Surgical to complement the body's normal healing process' in final paragraph
- Reference to reimbursement policies in risk factors bullet
- Reworded:
- Forward-looking statement risk factors bullet changed from 'the effects of current and future laws, rules, regulations and reimbursement policies relating to the labeling, marketing and sale of our products, and our planned launch of value-based wound, skin and other services' to 'the effects of current and future laws, rules and regulations relating to the labeling, marketing and sale of our products'
- OVERVIEW opening statement changed from 'Our products, services and technologies are designed to achieve our goal of providing better clinical outcomes at a lower overall cost for patients' to 'Our products are designed to achieve our goal of providing better clinical outcomes at a lower overall cost for healthcare systems'
- OVERVIEW description changed from 'expand our offerings for patients requiring treatments' to 'expand our offerings for patients requiring surgical treatments'
- Market description changed from 'We market and distribute surgical products to surgeons at hospitals and surgical centers' (newer) vs 'physicians, hospitals, clinics, and post-acute care settings' (older)
- Market focus changed from 'U.S. surgical tissue repair and advanced wound care markets' to 'U.S. surgical tissue repair market'
- Product pipeline description revised from 'extensive pipeline of innovative products under development' to 'strong pipeline of next-generation products'
- CellerateRX Surgical description in context: newer version includes TEXAGEN and ACTIGEN products not mentioned in older version
- Notes:
- The two filings appear to have different cutoff points in the MD&A section, with the newer filing's text being truncated mid-sentence at the end; comparison is limited to the available complete text
- Strategic focus shift from broader wound/skin services and post-acute care markets to surgical-focused offerings is evident but reflected in multiple cumulative wording changes rather than single discrete changes
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for SMTI — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding SMTI as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 454,449
- Reported value $10,720,453
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 5 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about SMTI's institutional holders → See what each manager we track holds →
Short interest (FINRA)
SMTI had 310,027 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
SMTI had 3.37% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 1.09 days to cover at the same settlement.
- Reported short interest (shares) 310,027
- Short interest (% of shares outstanding) 3.37%
- Prior settlement (shares) 280,418
- Reported change 10.56%
- Days to cover (reported) 1.09
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare SMTI vs…
SANARA MEDTECH INC is found in…
SMTI ranks in…
Frequently asked questions
What does SANARA MEDTECH INC (SMTI) do?
Sanara MedTech is a medical technology company that develops and commercializes surgical products for soft tissue repair and bone fusion. Its portfolio includes collagen-based wound management products, advanced surgical irrigation solutions, and various bone matrix implants used in operating rooms and sterile environments. The company focuses on enhancing clinical outcomes and reducing total healthcare costs by providing innovative surgical solutions.
What sector is SANARA MEDTECH INC (SMTI) in?
SANARA MEDTECH INC (SMTI) is classified in the Health Care sector. Its industry is surgical devices and biomaterials. It trades on NASDAQ.
Who are SANARA MEDTECH INC's (SMTI) competitors?
Notable peers of SANARA MEDTECH INC (SMTI) include MiMedx Group, Organogenesis, Stryker, Zimmer Biomet and Smith & Nephew. This peer set is informational only — not financial advice.
Is SANARA MEDTECH INC (SMTI) overbought or oversold right now?
SANARA MEDTECH INC (SMTI) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 63, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on SMTI come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.